Research on Innovative Traditional Chinese Medicine Diagnosis and Treatment Technologies for Diabetic Nephropathy Driven by Multi-Omics and Artificial Intelligence

Korábbi kezelés

• Currently taking Chinese herbal medicine or patent Chinese medicine with effects of tonifying deficiency, promoting blood circulation, or dispelling wind-dampness.

Más betegség

• Acute kidney injury or renal function impairment caused by other reasons (recent rapid decline in renal function, or kidney damage caused by drugs, infections, etc.);
• Other primary or secondary kidney diseases (such as systemic lupus erythematosus, polycystic kidney disease, etc.);
• Uncontrolled severe complications (such as severe cardiovascular disease, uncontrolled hypertension, severe infections, etc.);
• Critical organ failure (severe diseases of the heart, liver, or lungs);
• Drug allergy or clear contraindications (allergic to the study drug or its components);
• Abnormal coagulation function, or undergoing anticoagulant therapy (such as warfarin, rivaroxaban, etc.) with bleeding risk;

Egyéb

• Pregnancy or planned pregnancy (women currently pregnant or planning to become pregnant during the study);
• Non-cooperative or unable to follow the study protocol (unable or unwilling to comply with study requirements);

• Meets the clinical diagnostic criteria for diabetic nephropathy;
• Aged 18-75 years, any gender;
• eGFR >45 ml/min/1.73m²;
• 24-hour urine protein <2.0 g/day;
• Exhibits Traditional Chinese Medicine patterns of deficiency, stasis, or rheumatic symptoms;
• Willing to participate in the study, able to attend regular follow-ups, and provide informed consent;
• Has maintained a stable basic treatment plan (including hypoglycemic, antihypertensive, and lipid-lowering therapies) for ≥1 month prior to enrollment; during the first 3 months after enrollment, ARB, finerenone, and SGLT2 inhibitor therapies should generally not be adjusted.